{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T04:57:26Z","timestamp":1745470646789,"version":"3.40.4"},"reference-count":30,"publisher":"S. Karger AG","issue":"1","license":[{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathophysiol Haemos Thromb"],"published-print":{"date-parts":[[2007]]},"abstract":"<jats:p>Most invasive fungal infections such as candidemia are frequent in patients with hematologic malignancies. We measured cytokines\/chemokines (IL-6, IL-8, monocytic chemoattractant protein 1, RANTES and epithelial neutrophil-activating peptide 78), soluble molecules (sFas, sE-selectin and soluble vascular cell adhesion molecule 1) and platelet activation markers (soluble CD40 ligand, sP-selectin and platelet-derived microparticles) in patients with hematologic malignancies under prophylactic treatment with an antifungal drug (fosfluconazole). We classified patients into 2 groups by the level of \u03b2-&lt;i&gt;D&lt;\/i&gt;-glucan. The level of C-reactive protein was higher in the high \u03b2-&lt;i&gt;D&lt;\/i&gt;-glucan group (&gt;5 pg\/ml) than in the low \u03b2-&lt;i&gt;D&lt;\/i&gt;-glucan group. However, there were no differences in the levels of other parameters (peripheral blood cells, glutamic-oxaloacetic transaminase, glutamic-pyruvic transaminase, lactate dehydrogenase, blood urea nitrogen and creatinine). Patients in the high \u03b2-&lt;i&gt;D&lt;\/i&gt;-glucan group exhibited a significant elevation of several chemokines, soluble molecules and platelet activation markers compared with those in the low \u03b2-&lt;i&gt;D&lt;\/i&gt;-glucan group, but the levels of IL-8, monocytic chemoattractant protein 1 and sFas did not differ significantly. The levels of C-reactive protein and IL-6 increased significantly after 1 or 2 weeks on fosfluconazole in both groups. In contrast, the high \u03b2-&lt;i&gt;D&lt;\/i&gt;-glucan group exhibited a significant decrease in chemokines, soluble markers and platelet-derived microparticles compared with the low \u03b2-&lt;i&gt;D&lt;\/i&gt;-glucan group after treatment with fosfluconazole, although the patients in the low \u03b2-&lt;i&gt;D&lt;\/i&gt;-glucan group exhibited no significant changes. Furthermore, the levels of RANTES, epithelial neutrophil-activating peptide 78, soluble vascular cell adhesion molecule 1 and sE-selectin correlated positively with platelet-derived microparticles in the high \u03b2-&lt;i&gt;D&lt;\/i&gt;-glucan group. These findings suggest that fungal infection may modulate the vascular events in which some platelet-related chemokines are involved.<\/jats:p>","DOI":"10.1159\/000112637","type":"journal-article","created":{"date-parts":[[2008,3,7]],"date-time":"2008-03-07T10:47:34Z","timestamp":1204886854000},"page":"32-39","source":"Crossref","is-referenced-by-count":3,"title":["Elevation of Activated Platelet-Dependent Chemokines and Soluble Cell Adhesion Molecules in Patients with Hematologic Malignancies and High Levels of \u03b2-&lt;i&gt;D&lt;\/i&gt;-Glucan"],"prefix":"10.1159","volume":"36","author":[{"given":"S.","family":"Nomura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Iishii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Inami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Urase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2008,3,6]]},"reference":[{"doi-asserted-by":"publisher","key":"ref1","DOI":"10.1016%2FS1044-5323%2802%2900123-9"},{"doi-asserted-by":"publisher","key":"ref2","DOI":"10.1146%2Fannurev.immunol.15.1.675"},{"doi-asserted-by":"publisher","key":"ref3","DOI":"10.1084%2Fjem.176.2.587"},{"doi-asserted-by":"publisher","key":"ref4","DOI":"10.1074%2Fjbc.271.34.20545"},{"doi-asserted-by":"publisher","key":"ref5","DOI":"10.1159%2F000237097"},{"doi-asserted-by":"publisher","key":"ref6","DOI":"10.1097%2F00005792-200007000-00006"},{"doi-asserted-by":"publisher","key":"ref7","DOI":"10.1086%2F315193"},{"doi-asserted-by":"publisher","key":"ref8","DOI":"10.1128%2FIAI.69.8.5072-5079.2001"},{"doi-asserted-by":"publisher","key":"ref9","DOI":"10.1086%2F341660"},{"doi-asserted-by":"publisher","key":"ref10","DOI":"10.1016%2F0732-8893%2893%2990020-8"},{"doi-asserted-by":"publisher","key":"ref11","DOI":"10.1016%2F0009-8981%2894%2990110-4"},{"doi-asserted-by":"publisher","key":"ref12","DOI":"10.1002%2F%28SICI%291098-2825%281997%2911%3A2%3C73%3A%3AAID-JCLA1%3E3.0.CO%3B2-L"},{"doi-asserted-by":"publisher","key":"ref13","DOI":"10.1016%2FS0140-6736%2895%2991152-9"},{"doi-asserted-by":"publisher","key":"ref14","DOI":"10.1177%2F0091270003262799"},{"doi-asserted-by":"publisher","key":"ref15","DOI":"10.2133%2Fdmpk.20.485"},{"doi-asserted-by":"publisher","key":"ref16","DOI":"10.1016%2FS0002-9343%2897%2989455-7"},{"doi-asserted-by":"publisher","key":"ref17","DOI":"10.1086%2F421944"},{"doi-asserted-by":"publisher","key":"ref18","DOI":"10.1016%2FS0140-6736%2894%2990992-X"},{"doi-asserted-by":"publisher","key":"ref19","DOI":"10.1126%2Fscience.270.5243.1811"},{"doi-asserted-by":"publisher","key":"ref20","DOI":"10.1248%2Fbpb.26.233"},{"doi-asserted-by":"publisher","key":"ref21","DOI":"10.1128%2FIAI.68.3.1134-1141.2000"},{"doi-asserted-by":"publisher","key":"ref22","DOI":"10.1161%2F01.RES.0000160077.17427.57"},{"doi-asserted-by":"publisher","key":"ref23","DOI":"10.1016%2F0378-1119%2894%2990682-3"},{"doi-asserted-by":"publisher","key":"ref24","DOI":"10.1046%2Fj.1365-3148.2001.00340.x"},{"doi-asserted-by":"publisher","key":"ref25","DOI":"10.1016%2FS0049-3848%2898%2900161-3"},{"doi-asserted-by":"publisher","key":"ref26","DOI":"10.1086%2F516120"},{"doi-asserted-by":"publisher","key":"ref27","DOI":"10.1086%2F322802"},{"doi-asserted-by":"publisher","key":"ref28","DOI":"10.1128%2FAAC.48.8.3051-3056.2004"},{"doi-asserted-by":"publisher","key":"ref29","DOI":"10.1016%2FS0021-9150%2801%2900433-6"},{"doi-asserted-by":"publisher","key":"ref30","DOI":"10.1161%2F01.ATV.0000170133.43608.37"}],"container-title":["Pathophysiology of Haemostasis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/112637","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/112637","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T02:30:06Z","timestamp":1745461806000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000112637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2008,3,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000112637","archive":["Portico"],"relation":{},"ISSN":["1424-8832","1424-8840"],"issn-type":[{"type":"print","value":"1424-8832"},{"type":"electronic","value":"1424-8840"}],"subject":[],"published":{"date-parts":[[2007]]}}}